Shopping Cart
- Remove All
Your shopping cart is currently empty
Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $183 | In Stock | |
| 5 mg | $463 | In Stock | |
| 10 mg | $728 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,480 | In Stock |
| Description | Lirilumab (IPH2102) is an antibody against the lethal immunoglobulin-like receptor antibody KIR2D with antitumor activity that enhances the anti-HPV + cervical cancer activity of natural killer cells through VAV1-dependent NF-κB deinhibition. It can be used to study leukemia, head and neck squamous cell carcinoma (SCCHN). |
| In vivo | Treatment with Lirilumab (intravenous injection; once; 15 mg/kg) enhances the survival rate of mice injected with tumor[1]. |
| Synonyms | ONO-4483, IPH2102 |
| Molecular Weight | 145.52 kDa |
| Cas No. | 1000676-41-4 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.